These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34391596)

  • 21. Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents-The Data from the Study among Healthcare Workers in an Infectious Diseases Center.
    Skrzat-Klapaczyńska A; Kowalska JD; Paciorek M; Puła J; Bieńkowski C; Krogulec D; Stengiel J; Pawełczyk A; Perlejewski K; Osuch S; Radkowski M; Horban A
    Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
    Casas Fischer R
    Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long follow-up of BNT162b2 mRNA vaccine in healthcare workers (2020-2022): A retrospective longitudinal SARS-CoV-2 serological surveillance.
    De Pace V; Bruzzone B; Ricucci V; Calcavecchia N; Guarona G; Giberti I; Costa E; Ogliastro M; Galano B; Nigro N; Murgia D; Nanni L; Orsi A
    Hum Vaccin Immunother; 2023 Aug; 19(2):2258632. PubMed ID: 37724517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizer's BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study.
    Iwamoto M; Ukimura A; Ogawa T; Kawanishi F; Osaka N; Kubota M; Mori T; Sawamura R; Nishihara M; Suzuki T; Uchiyama K
    PLoS One; 2022; 17(5):e0268529. PubMed ID: 35576209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines.
    Pareek M; Sessa P; Polverino P; Sessa F; Kragholm KH; Sessa M
    Front Cardiovasc Med; 2023; 10():1210007. PubMed ID: 38075965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort Study.
    Muhsen K; Maimon N; Mizrahi A; Bodenheimer O; Cohen D; Maimon M; Grotto I; Dagan R
    Clin Infect Dis; 2022 Aug; 75(1):e755-e763. PubMed ID: 34698808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Symptomatic SARS-CoV-2 infections after full schedule BNT162b2 vaccination in seropositive healthcare workers: a case series from a single institution.
    Baj A; Novazzi F; Genoni A; Ferrante FD; Taborelli S; Pini B; Partenope M; Valli M; Gasperina DD; Capuano R; Prestia M; Spezia PG; Azzi L; Focosi D; Maggi F
    Emerg Microbes Infect; 2021 Dec; 10(1):1254-1256. PubMed ID: 34110974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response.
    Ontañón J; Blas J; de Cabo C; Santos C; Ruiz-Escribano E; García A; Marín L; Sáez L; Beato JL; Rada R; Navarro L; Sainz de Baranda C; Solera J
    EBioMedicine; 2021 Nov; 73():103656. PubMed ID: 34740112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.
    Chodick G; Tene L; Patalon T; Gazit S; Ben Tov A; Cohen D; Muhsen K
    JAMA Netw Open; 2021 Jun; 4(6):e2115985. PubMed ID: 34097044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.
    Monin L; Laing AG; Muñoz-Ruiz M; McKenzie DR; Del Molino Del Barrio I; Alaguthurai T; Domingo-Vila C; Hayday TS; Graham C; Seow J; Abdul-Jawad S; Kamdar S; Harvey-Jones E; Graham R; Cooper J; Khan M; Vidler J; Kakkassery H; Sinha S; Davis R; Dupont L; Francos Quijorna I; O'Brien-Gore C; Lee PL; Eum J; Conde Poole M; Joseph M; Davies D; Wu Y; Swampillai A; North BV; Montes A; Harries M; Rigg A; Spicer J; Malim MH; Fields P; Patten P; Di Rosa F; Papa S; Tree T; Doores KJ; Hayday AC; Irshad S
    Lancet Oncol; 2021 Jun; 22(6):765-778. PubMed ID: 33930323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in Spain.
    Fernández-Ciriza L; González Á; Del Pozo JL; Fernández-Montero A; Carmona-Torre F; Carlos S; Sarasa MDM; Reina G
    Sci Rep; 2022 Oct; 12(1):15606. PubMed ID: 36207324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.
    Sibbel S; McKeon K; Luo J; Wendt K; Walker AG; Kelley T; Lazar R; Zywno ML; Connaire JJ; Tentori F; Young A; Brunelli SM
    J Am Soc Nephrol; 2022 Jan; 33(1):49-57. PubMed ID: 34789546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of Infection and Duration of Protection after the Booster Dose of the Anti-SARS-CoV-2 Vaccine BNT162b2 among Healthcare Workers in a Large Teaching Hospital in Italy: Results of an Observational Study.
    Pascucci D; Grossi A; Lontano A; Marziali E; Nurchis MC; Grassi VM; Raponi M; Vetrugno G; Capelli G; Calabrò GE; Staiti D; Sanguinetti M; Damiani G; Laurenti P
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 - January 2022.
    Langlete P; Tesli M; Veneti L; Starrfelt J; Elstrøm P; Meijerink H
    Vaccine; 2023 Jun; 41(26):3923-3929. PubMed ID: 37211454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Healthcare workers highly affected during the COVID-19 epidemic wave in Poland prior to vaccination availability: seroprevalence study.
    Rosińska M; Stępień M; Kitowska W; Milczarek M; Juszczyk G; Nowacka Z; Gardel A; Hermann A; Bardoń-Błaszkowska A; Cudnik R; Czubak H; Wolniak-Bińkowska M; Źródłowska IA; Sadkowska-Todys M
    Med Pr; 2022 Apr; 73(2):109-123. PubMed ID: 35301511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26.COV2.S, and mRNA-1273: Gaining insight through the VAERS.
    Yan MM; Zhao H; Li ZR; Chow JW; Zhang Q; Qi YP; Wu SS; Zhong MK; Qiu XY
    Front Pharmacol; 2022; 13():921760. PubMed ID: 36419624
    [No Abstract]   [Full Text] [Related]  

  • 38. IgG anti-spike antibody levels in healthcare workers with and without prior COVID-19 up to 3 months after BNT162b2 vaccination.
    Van Elslande J; Weemaes M; Godderis L; Van Pottelbergh G; Bossuyt X; Vermeersch P
    Diagn Microbiol Infect Dis; 2022 Apr; 102(4):115638. PubMed ID: 35104720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune response to one dose of BNT162b2 mRNA Covid-19 vaccine followed by SARS-CoV-2 infection: An Italian prospective observational study.
    Stefanizzi P; Larocca AMV; Martinelli A; Soldano S; Dell'Aera M; Migliore G; Germinario CA; Vimercati L; Tafuri S; Bianchi FP
    Vaccine; 2022 Mar; 40(12):1805-1809. PubMed ID: 35190212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals.
    Lozano-Rodríguez R; Avendaño-Ortíz J; Terrón V; Montalbán-Hernández K; Casalvilla-Dueñas J; Bergón-Gutiérrez M; Mata-Martínez P; Martín-Quirós A; García-Garrido MÁ; Del Balzo-Castillo Á; Peinado M; Gómez L; Llorente-Fernández I; Martín-Miguel G; Herrero-Benito C; López-Morejón L; Vela-Olmo C; Cubillos-Zapata C; López-Collazo E; Del Fresno C
    Front Immunol; 2023; 14():1136029. PubMed ID: 37153580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.